AND EXCHANGE COMMISSION
to Section 13 or 15(d)
the Securities Exchange Act of 1934
of report (Date of earliest event reported): August 17, 2016
name of registrant as specified in its charter)
or other jurisdiction
West 2100 South
Lake City, UT
of principal executive offices)
telephone number, including area code: (801) 839-3500
Name or Former Address, if Changed Since Last Report)
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
August 19, 2016, Amedica Corporation (“Amedica” or “the Company”) issued a press release relating to a
notification from the NASDAQ OMX GROUP (“Nasdaq”). On August 17, 2016, the Company received a letter from Nasdaq stating
that the bid price of the Company’s common stock for the last 30 consecutive trading days had closed below the minimum $1.00
per share required for continued listing under Listing Rule 5550(a)(2).
Nasdaq notification letter does not result in the immediate delisting of the Company’s common stock, and the stock will
continue to trade uninterrupted on the The Nasdaq Capital Market under the symbol “AMDA”.
management intends to resolve the situation to allow for continued listing on The Nasdaq Capital Market.
is provided a grace period of 180-calendar days, or until February 13, 2017, to regain compliance with the minimum bid price requirement.
If at any time during the 180-day grace period, the minimum closing bid price per share of the Company’s common stock closes
at or above $1.00 for a minimum of ten consecutive business days, Amedica will regain compliance and the matter will be closed.
In the event the Company does not regain compliance within this grace period, it may be eligible to receive an additional 180-day
grace period; provided that Amedica meets the continued listing requirement for market value of publicly held shares and all other
initial listing standards for The Nasdaq Capital Market, with the exception of the minimum bid price requirement, and provides
written notice of its intention to cure the minimum bid price deficiency during the second 180-day grace period, by effecting
a reverse stock split, if necessary. If it appears to the Nasdaq staff that the Company will not be able to cure the deficiency
or if the Company is not otherwise eligible for the additional grace period, the Company’s common stock will be subject
to delisting by Nasdaq.
copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
9.01 Financial Statements and Exhibits.
Release dated August 19, 2016.|
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
August 19, 2016
Financial Officer |